Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling

Author:

Epling-Burnette P. K.12,Sokol Lubomir3,Chen Xianhong1,Bai Fanqi1,Zhou Junmin1,Blaskovich Michelle A.1,Zou JianXiang1,Painter Jeffrey S.1,Edwards Todd D.4,Moscinski Lynn5,Yoder Jeffrey A.6,Djeu Julie Y.1,Sebti Said1,Loughran Thomas P.7,Wei Sheng1

Affiliation:

1. H. Lee Moffitt Cancer Center and Research Institute Immunology Program, Department of Interdisciplinary Oncology,

2. James A. Haley Veterans Administration Hospital, and

3. H. Lee Moffitt Cancer Center and Research Institute, Malignant Hematology Division, Department of Interdisciplinary Oncology, University of South Florida, Tampa;

4. The Stern Cardiovascular Center Wolf River, Germantown, TN;

5. H. Lee Moffitt Cancer Center and Research Institute, Pathology Division, Department of Interdisciplinary Oncology, University of South Florida, Tampa;

6. Department of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh; and

7. Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey

Abstract

Abstract Large granular lymphocyte (LGL) leukemia is commonly associated with poor hematopoiesis. The first case of pulmonary artery hypertension (PAH) was observed in a 57-year-old woman with natural killer (NK)–LGL leukemia and transfusion-dependent anemia. Using a genetic approach, we demonstrated that killing of pulmonary endothelial cells by patient NK cells was mediated by dysregulated balance in activating and inhibitory NK-receptor signaling. Elevated pulmonary artery pressure and erythroid differentiation improved after disrupting the NK-receptor signaling pathway with 4 courses of a farnesyltransferase inhibitor, tipifarnib. Coincidental association between PAH and LGL leukemia suggest a causal relationship between the expanded lymphocyte population and these clinical manifestations. This trial is registered at www.ClinicalTrials.gov as NCI 6823.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3